title: [Cell-based therapies - an innovative therapeutic option in ophthalmology: Treating corneal diseases with stem cells].
abstract: Pathological changes and disorders of the cornea are a major cause of severe visual impairment and blindness. Replacement of a pathologically altered cornea with healthy corneal tissue from the eye of a suitable donor is among the most common and successful transplantation procedures in medicine. In Germany, approximately 5000-6000 corneal transplantations are performed each year, but the total demand per year is estimated to be twice as high. With a success rate of 90%, the outcome of cornea transplantation is very favourable. However, long-term maintenance and regeneration of a healthy new cornea requires tissue-specific corneal stem cells residing at the basal layer of the limbus, which is the annular transition zone between the cornea and sclera. When this important limbal stem cell population is destroyed or dysfunctional, a pathological condition known as limbal stem cell deficiency (LSCD) manifests. Limbal stem cell deficiency describes conditions associated with impaired corneal wound healing and regeneration. In this situation, transplantation of healthy limbal stem cells is the only curative treatment approach for restoration of an intact and functional ocular surface. To date, treatment of LSCD presents a great challenge for ophthalmologists. However, innovative, cell-therapeutic approaches may open new, promising treatment perspectives. In February 2015, the European Commission granted marketing authorization to the first stem cell-based treatment in the European Union. The product named Holoclar® is an advanced therapy medicinal product (ATMP) for the treatment of moderate to severe LSCD due to physical and chemical burns in adults. Further cell-based treatment approaches are in clinical development.
authors.affiliation: Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland. Ann-Christin.Bakker@pei.de.
authors.forename: Ann-Christin
authors.initials: AC
authors.lastname: Bakker
authors.affiliation: Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Langer
mesh_terms: D000328:Adult; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D003316:Corneal Diseases / Q000628:therapy*; D016039:Corneal Transplantation / Q000379:methods*; D005858:Germany; D006801:Humans; D016850:Limbus Corneae; D040541:Marketing / Q000331:legislation & jurisprudence; D033581:Stem Cell Transplantation / Q000379:methods*; D035703:Therapies, Investigational / Q000379:methods*
keywords: Cornea; Holoclar; Keratoplasty; Limbal stem cell deficiency; Limbus